PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
11.72%
Net income growth above 1.5x AVGO's 3.47%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
15.25%
D&A growth well above AVGO's 0.21%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
-233.87%
Both lines show negative yoy. Martin Whitman would see an industry or cyclical factor reducing tax deferrals for both players.
3.76%
Less SBC growth vs. AVGO's 16.18%, indicating lower equity issuance. David Dodd would confirm the firm still retains key staff.
-99.30%
Both reduce yoy usage, with AVGO at -263.27%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
-26.02%
Both yoy AR lines negative, with AVGO at -131.09%. Martin Whitman would suspect an overall sector lean approach or softer demand.
-10.92%
Both reduce yoy inventory, with AVGO at -242.50%. Martin Whitman would find a widespread caution or cyclical demand drop in the niche.
-65.33%
Negative yoy AP while AVGO is 713.33%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
-114.65%
Both reduce yoy usage, with AVGO at -73.94%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
7.14%
Lower 'other non-cash' growth vs. AVGO's 189.47%, indicating steadier reported figures. David Dodd would confirm no missed necessary write-downs or gains.
-46.66%
Both yoy CFO lines are negative, with AVGO at -9.30%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-16.28%
Negative yoy CapEx while AVGO is 10.40%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
13.38%
Purchases growth of 13.38% while AVGO is zero at 0.00%. Bruce Berkowitz sees a mild difference in portfolio building that might matter for returns.
21.18%
We have some liquidation growth while AVGO is negative at -33.33%. John Neff notes a short-term liquidity advantage if competitor is holding or restricted.
154.59%
We have some outflow growth while AVGO is negative at -99.46%. John Neff sees competitor possibly pulling back more aggressively from minor expansions or intangible invests.
127.20%
Investing outflow well above AVGO's 66.98%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-203.03%
We cut yoy buybacks while AVGO is 26.54%. Joel Greenblatt would question if competitor is gaining a per-share edge unless expansions justify holding cash here.